Loading…
Belle Health LLC was warned for offering compounded semaglutide and tirzepatide drug products with false or misleading claims under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act. The company's website displayed product labels identifying "Belle" as the compounder of these drugs when Belle was not actually the compounder, making the products misbranded. This representation violated the prohibition on introducing misbranded drugs into interstate commerce under section 301(a) of the FDCA. The FDA conducted a website review in December 2025 and determined the false compounder attribution constituted a prohibited act.